Payment overview · 2025
General Payments
$259.96
7 reported records · 7 companies
Healthcare provider profile · identity verified
Scott D Kaiser, MD
Allopathic & Osteopathic Physicians|Family Medicine · DENVER, CO · NPI 1093799215
Verified facts
What the public records show
CMS Open Payments records show Scott D Kaiser, MD received $259.96 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.80 | 48.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.87 | 12.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.17 | 10.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.84 | 9.2% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $22.07 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.00 | 6.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $11.21 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $259.96 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.87 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $11.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 710 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 94 |
| Lisinopril | Lisinopril | 280 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 185 | 59 |
| Losartan Potassium | Losartan Potassium | 155 | 46 |
| Omeprazole | Omeprazole | 143 | 52 |
| Metformin Hcl | Metformin Hcl | 132 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 33 |
| Ezetimibe | Ezetimibe | 106 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 29 |
| Jardiance | Empagliflozin | 86 | 23 |
| Meloxicam | Meloxicam | 85 | 39 |
| Metformin Hcl Er | Metformin Hcl | 84 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 22 |
| Simvastatin | Simvastatin | 76 | 21 |
| Trazodone Hcl | Trazodone Hcl | 74 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 26 |
| Eliquis | Apixaban | 58 | 21 |
| Gabapentin | Gabapentin | 56 | 21 |
| Finasteride | Finasteride | 55 | 19 |
| Allopurinol | Allopurinol | 51 | 17 |
| Furosemide | Furosemide | 51 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 26 |
| Alendronate Sodium | Alendronate Sodium | 48 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 14 |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Prednisone | Prednisone | 45 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Carvedilol | Carvedilol | 43 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | 14 |
| Xarelto | Rivaroxaban | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Montelukast Sodium | Montelukast Sodium | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 17 |
| Sertraline Hcl | Sertraline Hcl | 37 | 14 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 15 |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Famotidine | Famotidine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $259.96 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEXSERO, Cologuard Collection Kit, ImmunoCAP, NEXPLANON, SYMPLICITY G3, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error